Chase Investment Counsel Corp Buys New Shares in Lantheus Holdings, Inc. $LNTH

Chase Investment Counsel Corp purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,000 shares of the medical equipment provider’s stock, valued at approximately $2,218,000.

A number of other large investors also recently bought and sold shares of the stock. Versant Capital Management Inc grew its stake in shares of Lantheus by 33.0% during the 2nd quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock valued at $65,000 after buying an additional 146 shares during the period. Abel Hall LLC increased its holdings in shares of Lantheus by 4.6% during the 1st quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock worth $297,000 after buying an additional 172 shares during the last quarter. Smartleaf Asset Management LLC raised its position in shares of Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 197 shares during the period. GAMMA Investing LLC raised its position in shares of Lantheus by 6.4% in the 2nd quarter. GAMMA Investing LLC now owns 3,348 shares of the medical equipment provider’s stock worth $371,000 after buying an additional 202 shares during the period. Finally, Vident Advisory LLC boosted its holdings in Lantheus by 0.5% in the fourth quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock valued at $2,979,000 after acquiring an additional 230 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. TD Cowen downgraded Lantheus from a “buy” rating to a “hold” rating and lowered their price target for the company from $110.00 to $102.50 in a research report on Monday, August 3rd. B. Riley Financial reaffirmed a “buy” rating on shares of Lantheus in a research note on Wednesday, July 29th. William Blair set a $102.50 target price on Lantheus in a report on Monday, August 3rd. The Goldman Sachs Group reiterated a “neutral” rating and set a $94.00 target price on shares of Lantheus in a report on Thursday, May 7th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a research report on Monday, June 29th. Five equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Lantheus has a consensus rating of “Hold” and a consensus target price of $108.11.

Lantheus Price Performance

Shares of Lantheus stock opened at $100.95 on Monday. Lantheus Holdings, Inc. has a twelve month low of $49.67 and a twelve month high of $111.86. The stock has a market cap of $6.59 billion, a price-to-earnings ratio of 24.38 and a beta of -0.03. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. The company has a fifty day moving average price of $104.23 and a 200 day moving average price of $89.34.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating the consensus estimate of $1.30 by $0.25. The company had revenue of $388.18 million for the quarter, compared to analyst estimates of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The firm’s revenue was up 2.7% compared to the same quarter last year. During the same period last year, the company posted $1.57 earnings per share. Equities research analysts forecast that Lantheus Holdings, Inc. will post 4.5 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.